mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

Maxwell Biotech Group

Products

PRODUCTS

Tuberculosis causes enormous social and economic damage due to the fact that, in general, it affects the working age population, requires long-term care, medical examination and hospitalization, and it needs prevention and anti-relapse measures.

To date the Company develops 2 antituberculosis drugs: SQ109 and Q203.

SQ109

SQ109 based on the development of the U.S. biotechnology company Sequella, is one of some antituberculosis drugs that are at the late phase of clinical development. Load more…

Q203

The second drug Q203 licensed from Korean biotechnology company Qurient Co Ltd, is the first in new class of amide imidazopyridine compounds. Q203 has a unique mechanism of action against M. tuberculosis. Load more…

Top